{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-024646","form_type":"8-K","ticker":"NUWE","cik":"0001506492","company_name":"Nuwellis, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.727442+00:00","generated_at":"2026-06-02T17:49:44.932488+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nuwellis Q1 revenue up 2% to $1.9M; net loss narrows to $3.8M","bullets":["Revenue $1.9M, +2% YoY; consumables sales +11% to 82% of total revenue.","Gross margin 64.1% vs 58.4%; operating loss improved to $4.7M from $5.8M prior year.","Net loss $3.8M ($0.60 loss per share) vs $6.5M ($5.76 loss per share) YoY.","Cash $1.4M, no debt; closed $2.7M underwritten public offering on April 30, 2024.","Plans approx. 50% expense reduction for rest of 2024; launched REVERSE-HF clinical study."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-024646","json":"https://secwatch.observer/filing/0001140361-24-024646.json","markdown":"https://secwatch.observer/filing/0001140361-24-024646.md","text":"https://secwatch.observer/filing/0001140361-24-024646.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506492/000114036124024646/0001140361-24-024646-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506492/000114036124024646/ef20028479_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T17:49:44.932488+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2ef367beaf7d430a7922e997e42f2eead996990f","claim":"Nuwellis, Inc. reported the first quarter ended March 31, 2024 results: revenue $1.9 million, net income $3.8 million, EPS a loss of $0.60 per basic and diluted common share.","evidence_excerpt":"company focused on transforming the lives of people with fluid overload, today reported financial results for the first quarter ended March 31, 2024. Highlights: • Revenue of $1.9 million, a 2% increase over the prior-year period. • Consumables sales, representing 82% of total revenue, grew 11% year-over-year. • Pediatric revenue growth of 40% year over year led","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506492/000114036124024646/0001140361-24-024646-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$1.9 million"},{"label":"Net income","value":"$3.8 million"},{"label":"EPS","value":"a loss of $0.60 per basic and diluted common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}